Koi Peptides Expands Research Catalog With HPLC-Verified Reference Compounds
The expansion targets analytical and preclinical research settings — not finished formulations or consumer supplementat…
The expansion targets analytical and preclinical research settings — not finished formulations or consumer supplementat…
As biologics complexity grows, contract development organizations are investing in end-to-end analytical infrastructure…
A recent executive order places ibogaine among prioritized psychedelic compounds, signaling a potential regulatory path…
The RMAT designation accelerates development dialogue with FDA — a regulatory milestone operators in the immunology-adj…
The Austin-based biotech's lead candidate targets the DR3 pathway — a mechanism drawing growing interest in immune-medi…
As bioactive ingredient validation demands tighten, contract development organizations with end-to-end analytical infra…
The CDMO's integrated testing infrastructure targets a critical bottleneck in biologics development: closing the gap be…
The Dutch CDMO signals growing demand for end-to-end analytical support as biotech sponsors accelerate vaccine and biol…
New data across three high-complexity populations could reshape how formulators and clinicians think about insulin-deli…
In-country fulfillment and certificate-of-analysis verification anchor the expansion as demand for research-grade pepti…
From antioxidant-rich spice blends to probiotic-forward sauces, operators are eyeing the $5B+ condiment category for be…
The children's meal-kit segment is leaning into developmental and behavioral outcomes as operators seek differentiation…